{"id":54303,"date":"2026-01-16T19:58:05","date_gmt":"2026-01-16T11:58:05","guid":{"rendered":"https:\/\/flcube.com\/?p=54303"},"modified":"2026-01-16T19:58:06","modified_gmt":"2026-01-16T11:58:06","slug":"vitalgens-vgn-r08b-gene-therapy-earns-fda-orphan-drug-designation-for-gaucher-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54303","title":{"rendered":"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease"},"content":{"rendered":"\n<p><strong>Shanghai Vitalgen BioPharma Co., Ltd.<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Orphan Drug Designation (ODD)<\/strong> to <strong>VGN\u2011R08b<\/strong>, an <strong>adeno\u2011associated virus (AAV) gene therapy<\/strong> for the treatment of <strong>Gaucher disease<\/strong>, a rare inherited lysosomal storage disorder caused by <strong>GBA1 gene mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Vitalgen BioPharma Co., Ltd.<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>VGN\u2011R08b (recombinant AAV gene therapy)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Orphan Drug Designation (ODD)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Gaucher disease (GBA1 gene mutations)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Delivers functional GBA1 gene to restore glucocerebrosidase (GCase) activity<\/td><\/tr><tr><td><strong>Previous Designations<\/strong><\/td><td>Rare Pediatric Disease Designation (RPDD) and Fast Track Designation (FTD) (both FDA, 2025)<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Pre\u2011clinical; IND\u2011enabling studies ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-profile-gaucher-disease\">Disease Profile: Gaucher Disease<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Etiology:<\/strong> Autosomal recessive disorder caused by <strong>GBA1 gene mutations<\/strong> leading to insufficient <strong>glucocerebrosidase (GCase)<\/strong> activity<\/li>\n\n\n\n<li><strong>Pathophysiology:<\/strong> Accumulation of glucocerebroside substrates in <strong>macrophages<\/strong> of liver, spleen, bone marrow, and brain<\/li>\n\n\n\n<li><strong>Clinical Manifestations:<\/strong><\/li>\n\n\n\n<li><strong>Hepatosplenomegaly<\/strong> (enlarged liver and spleen)<\/li>\n\n\n\n<li><strong>Skeletal erosion<\/strong> and bone pain<\/li>\n\n\n\n<li><strong>Neurological damage<\/strong> (in neuronopathic forms)<\/li>\n\n\n\n<li><strong>Anemia, thrombocytopenia, and growth failure<\/strong><\/li>\n\n\n\n<li><strong>Epidemiology:<\/strong><\/li>\n\n\n\n<li><strong>Global incidence:<\/strong> 1 in 40,000\u2011100,000 live births<\/li>\n\n\n\n<li><strong>China:<\/strong> ~500\u2011800 prevalent cases<\/li>\n\n\n\n<li><strong>US:<\/strong> ~6,000 prevalent cases<\/li>\n\n\n\n<li><strong>EU:<\/strong> ~10,000 prevalent cases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gene Therapy Design:<\/strong> <strong>Recombinant AAV vector<\/strong> engineered to deliver a <strong>functional GBA1 gene<\/strong> to target tissues<\/li>\n\n\n\n<li><strong>Restoration of GCase:<\/strong> Therapy aims to <strong>restore enzymatic activity at the source<\/strong>, correcting metabolic abnormalities and preventing\/reversing organ damage<\/li>\n\n\n\n<li><strong>CNS Penetration:<\/strong> Designed to <strong>cross the blood\u2011brain barrier<\/strong> to address <strong>neuronopathic Gaucher disease<\/strong>, the most severe form<\/li>\n\n\n\n<li><strong>Advantage:<\/strong> <strong>Single\u2011administration<\/strong> curative potential vs. <strong>lifelong enzyme replacement therapy (ERT)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>US<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Gaucher Patients<\/strong><\/td><td>500\u2011800<\/td><td>6,000<\/td><td>20,000<\/td><\/tr><tr><td><strong>Neuronopathic Forms<\/strong><\/td><td>150\u2011250<\/td><td>1,800<\/td><td>6,000<\/td><\/tr><tr><td><strong>Annual ERT Cost<\/strong><\/td><td>$300,000<\/td><td>$300,000<\/td><td>$300,000<\/td><\/tr><tr><td><strong>Gene Therapy Price<\/strong><\/td><td>$1.5\u20112.0\u202fmillion<\/td><td>$2.0\u20113.5\u202fmillion<\/td><td>$2.0\u20113.5\u202fmillion<\/td><\/tr><tr><td><strong>VGN\u2011R08b Peak Revenue<\/strong><\/td><td>\u00a5300\u202fmillion<\/td><td>$600\u202fmillion<\/td><td>$1.2\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ERTs:<\/strong> Cerezyme (Sanofi), VPRIV (Takeda) \u2013 require <strong>biweekly IV infusions<\/strong> for life<\/li>\n\n\n\n<li><strong>Substrate Reduction:<\/strong> Cerdelga (Sanofi) \u2013 oral, limited to non\u2011neuronopathic forms<\/li>\n\n\n\n<li><strong>Gene Therapies:<\/strong><\/li>\n\n\n\n<li><strong>Prevail Therapeutics<\/strong> (PR001) \u2013 Phase\u202fI\/II for neuronopathic GD<\/li>\n\n\n\n<li><strong>AVROBIO<\/strong> \u2013 Pre\u2011clinical<\/li>\n\n\n\n<li><strong>VGN\u2011R08b<\/strong> \u2013 <strong>Only AAV gene therapy<\/strong> with <strong>triple FDA designations<\/strong> (ODD, RPDD, FTD)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Triple FDA designations demonstrate <strong>regulatory confidence<\/strong> and accelerate development timeline<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Vitalgen\u2019s <strong>Shanghai AAV facility<\/strong> (capacity 2,000 doses\/year) will produce clinical material; scale\u2011up to commercial capacity by 2028<\/li>\n\n\n\n<li><strong>Clinical Path:<\/strong> <strong>IND filing<\/strong> planned for <strong>Q3\u202f2026<\/strong>; <strong>Phase\u202fI\/II trial<\/strong> initiation Q1\u202f2027; <strong>potential accelerated approval<\/strong> based on surrogate endpoints<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Vitalgen seeking <strong>ex\u2011China partnerships<\/strong> for US\/EU commercialization; <strong>potential deal value $500\u2011800\u202fmillion<\/strong> upon Phase\u202fI success<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for VGN\u2011R08b. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[24,417],"class_list":["post-54303","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-rare-orphan-disease-drugs","tag-vitalgen-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to VGN\u2011R08b, an adeno\u2011associated virus (AAV) gene therapy for the treatment of Gaucher disease, a rare inherited lysosomal storage disorder caused by GBA1 gene mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54303\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease\" \/>\n<meta property=\"og:description\" content=\"Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to VGN\u2011R08b, an adeno\u2011associated virus (AAV) gene therapy for the treatment of Gaucher disease, a rare inherited lysosomal storage disorder caused by GBA1 gene mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54303\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T11:58:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-16T11:58:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54303#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54303\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease\",\"datePublished\":\"2026-01-16T11:58:05+00:00\",\"dateModified\":\"2026-01-16T11:58:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54303\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Rare \\\/ orphan disease drugs\",\"Vitalgen BioPharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54303#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54303\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54303\",\"name\":\"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-16T11:58:05+00:00\",\"dateModified\":\"2026-01-16T11:58:06+00:00\",\"description\":\"Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to VGN\u2011R08b, an adeno\u2011associated virus (AAV) gene therapy for the treatment of Gaucher disease, a rare inherited lysosomal storage disorder caused by GBA1 gene mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54303#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54303\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54303#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to VGN\u2011R08b, an adeno\u2011associated virus (AAV) gene therapy for the treatment of Gaucher disease, a rare inherited lysosomal storage disorder caused by GBA1 gene mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54303","og_locale":"en_US","og_type":"article","og_title":"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease","og_description":"Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to VGN\u2011R08b, an adeno\u2011associated virus (AAV) gene therapy for the treatment of Gaucher disease, a rare inherited lysosomal storage disorder caused by GBA1 gene mutations.","og_url":"https:\/\/flcube.com\/?p=54303","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-16T11:58:05+00:00","article_modified_time":"2026-01-16T11:58:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54303#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54303"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease","datePublished":"2026-01-16T11:58:05+00:00","dateModified":"2026-01-16T11:58:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54303"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Rare \/ orphan disease drugs","Vitalgen BioPharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54303#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54303","url":"https:\/\/flcube.com\/?p=54303","name":"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-16T11:58:05+00:00","dateModified":"2026-01-16T11:58:06+00:00","description":"Shanghai Vitalgen BioPharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to VGN\u2011R08b, an adeno\u2011associated virus (AAV) gene therapy for the treatment of Gaucher disease, a rare inherited lysosomal storage disorder caused by GBA1 gene mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54303#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54303"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54303#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vitalgen\u2019s VGN\u2011R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54303"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54303\/revisions"}],"predecessor-version":[{"id":54404,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54303\/revisions\/54404"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}